TMIS | Evolocumab + Dr. Haussler
This month in science…
We learned that evolocumab, a monoclonal antibody inhibiting proprotein convertase subtilisin-kexin type 9 (PCSK9), reduces low-density lipoprotein (LDL) cholesterol levels.
Read MoreInterview
The University of Arizona College of Medicine ‒ Phoenix Student Publication
This month in science…
We learned that evolocumab, a monoclonal antibody inhibiting proprotein convertase subtilisin-kexin type 9 (PCSK9), reduces low-density lipoprotein (LDL) cholesterol levels.
Read More